CAJ | 학술논문

目的：观察他克莫司治疗特发性膜性肾病的临床效果，探讨其临床应用价值。方法：选取2011年7月—2013年6月特发性膜性肾病患者44例，患者根据自身经济条件自愿选择药物，进入两个治疗小组，列入观察队列。其中他克莫司组22例，环磷酰胺组22例，为环磷酰胺组患者应用环磷酰胺+泼尼松/甲基泼尼松龙治疗；为他克莫司组患者应用他克莫司治疗，对比两组患者的临床治疗效果以及不良反应发生情况。结果：治疗后，他克莫司组血清白蛋白水平为（38.79±6.21）g/L，血肌酐水平为（106.23±13.62）μmol/L，肾小球滤过率为（86.65±6.65）ml/min，24h尿蛋白定量为（1.52±0.32）g/24h，胆固醇为（6.21±1.32） mmol/L，特发性膜性肾病总缓解率为95.5%，不良反应发生率为9.1%，以上数据与环磷酰胺组比较，具有统计学意义（P<0.05）。结论：他克莫司治疗特发性膜性肾病患者，疗效确切，安全性高，值得临床进一步应用、推广。
목적：관찰타극막사치료특발성막성신병적림상효과，탐토기림상응용개치。방법：선취2011년7월—2013년6월특발성막성신병환자44례，환자근거자신경제조건자원선택약물，진입량개치료소조，렬입관찰대렬。기중타극막사조22례，배린선알조22례，위배린선알조환자응용배린선알+발니송/갑기발니송룡치료；위타극막사조환자응용타극막사치료，대비량조환자적림상치료효과이급불량반응발생정황。결과：치료후，타극막사조혈청백단백수평위（38.79±6.21）g/L，혈기항수평위（106.23±13.62）μmol/L，신소구려과솔위（86.65±6.65）ml/min，24h뇨단백정량위（1.52±0.32）g/24h，담고순위（6.21±1.32） mmol/L，특발성막성신병총완해솔위95.5%，불량반응발생솔위9.1%，이상수거여배린선알조비교，구유통계학의의（P<0.05）。결론：타극막사치료특발성막성신병환자，료효학절，안전성고，치득림상진일보응용、추엄。
Objective Observe the tacrolimus for treatment of idiopathic membranous nephropathy, explore its clinical application value. Methods Choose between July 2011 to June 2013 in 44 patients with idiopathic membranous nephropathy, divided into two treatment groups, tacrolimus group of 22 cases, cyclophosphamide group of 22 cases . Comparison of the two groups of patients with clinical therapeutic effects and adverse reactions.Results After treatment, the tacrolimus group of serum albumin levels for(38.79 ± 6.21) g/L, the serum creatinine level for(106.23±13.62)mu mol/L, glomerular filtration rate was (86.65 ±6.65)ml/min, the 24 h urine protein is (1.52 ± 0.32 g / 24 h, cholesterol is (6.21 ±1.32) y/L. Idiopathic membranous nephropathy overall response rate was 95.5%, the incidence of adverse reactions was 9.1%. The above data is compared with cyclophosphamide group, with statistical significance (P < 0.05).Conclusions Tacrolimus treatment of idiopathic membranous nephropathy, curative effect, high safety, worth clinical promotion.